Interpreting CHARISMA study: Dual anti platelet therapy

CHARISMA was a prospective, randomized,double-blind, placebo-controlled study of the
efficacy and safety of clopidogrel plus aspirin vs placebo plus aspirin in patients at high risk
of cardiovascular events.
This study has shown that in asymptomatic patients( patients with cardio-cerebro-peripheral vascular disease(CCP- VD) the absolute rask reduction of 1%(RRR 13%) but in asymptomatic patients ( multiple risk factors without CCP-VD) there was no benefit.

Do not waste resources.